Enrolling ACRIA Trials

• Ampligen and HAART: Protocol AMP 719
• Ampligen and Treatment Interruptions: Protocol AMP 720

Ampligen and HAART: Protocol AMP 719

This trial will study the effects and safety of adding Ampligen to HAART and see if it helps to lower viral load.

Adults with a CD4 count over 300, and a viral load between 500 and 30,000 may be eligible for this study. The first 10 people in the trial will receive infusions of Ampligen twice a week, and take HAART. Later groups will either receive infusions at entry or receive them 6 months later.

The study will last 48 weeks during which time participants will make 21 visits to ACRIA. All blood tests, study visits and study drugs will be provided at no charge to the participants. Once enrolled in the study, there will be a reimbursement of $25 per visit to cover lost time from work, transportation costs and/or meals.

For more information, call Dr. Douglas Mendez at 212-924-3934, ext. 126.

Ampligen and Treatment Interruptions: Protocol AMP 720

This trial will study whether Ampligen can extend the time people can interrupt HAART, before viral load rebounds.

Adults who are taking HAART, and who have a CD4 count over 400 and viral load below 50, will take HAART and receive infusions of Ampligen, or take HAART without Ampligen, for 2 months. Then, HAART will be stopped and viral load will be checked weekly. If viral load rises above 5,000, HAART will be restarted. If viral load drops below 50 for 2 months, HAART will be stopped again. This pattern will continue for the rest of the study. People who don't receive Ampligen can take it after 14 months.

The study will last approximately 128 weeks during which time participants will make 128 visits to ACRIA. All blood tests, study visits and study drug will be provided at no charge to the participants. Once enrolled in the study, there will be a reimbursement of $25 per visit to cover lost time from work, transportation costs and/or meals.

For more information, call Dr. Douglas Mendez at 212-924-3934 ext 126.